Unichem Labs gets USFDA nod to Cyclobenzaprine Hydrochloride Tablets to treat muscle spasm

Cyclobenzaprine HCl Tablets are indicated for the treatment as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Published On 2020-07-08 07:10 GMT   |   Update On 2020-07-08 07:10 GMT
Advertisement

Mumbai: Unichem Laboratories Limited has received ANDA approval for its Cyclobenzaprine Hydrochloride Tablets USP, 5 mg, 7.5 mg and 10 mg from the United States Food and Drug Administration (USFDA) to market a generic version of FLEXERIL® (Cyclobenzaprine HCl) Tablets, 5 mg and 10 mg of Janssen Research and Development LLC.

Cyclobenzaprine HCl Tablets are indicated for the treatment as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. The product will be commercialized from Unichem's Goa plant.

Advertisement

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. 

Read also: Unichem Labs gets USFDA EIR for Roha API facility



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News